Classifications: antiulcer; Therapeutic: antiulcer
Pregnancy Category: B
1 g tablets; 1 g/10 mL suspension
A complex of aluminum hydroxide and sulfated sucrose. Following oral administration, sucralfate and gastric acid react to
form a viscous, adhesive, paste-like substance that resists further reaction with gastric acid. This "paste" adheres
to the GI mucosa with a major portion binding electrostatically to the positively charged protein molecules in the damaged
mucosa of an ulcer crater or an acute gastric erosion caused by alcohol or other drugs.
Absorbs bile, inhibits the enzyme pepsin, and blocks back diffusion of H+ ions. These actions plus adherence of the paste-like complex protect damaged mucosa against further destruction from ulcerogenic
secretions and drugs.
Short-term (up to 8 wk) treatment of duodenal ulcer.
Short-term treatment of gastric ulcer, aspirin-induced erosions, suspension for chemotherapy-induced mucositis.
Pregnancy (category B). Safety and efficacy in children are not established.
Chronic kidney failure or dialysis due to aluminum accumulation; renal impairment.
Route & Dosage
Adult: PO 1 g q.i.d. 1 h a.c. and h.s. PO Maintenance 1 g b.i.d.
- Use drug solubilized in an appropriate diluent by a pharmacist when given through nasogastric tube.
- Administer antacids prescribed for pain relief 30 min before or after sucralfate.
- Separate administration of QUINOLONES, digoxin, phenytoin, tetracycline from that of sucralfate by 2 h to prevent sucralfate from binding to these compounds
in the intestinal tract and reducing their bioavailability.
- Store in tight container at room temperature, 15°30° C (59°86° F). Stable for 2 y after manufacture.
Adverse Effects (≥1%)GI:
Nausea, gastric discomfort, constipation, diarrhea
May decrease absorption of quinolones
(e.g., ciprofloxacin, norfloxacin
), digoxin, phenytoin, tetracycline.
Minimally absorbed from GI tract (<5%). Duration:
Up to 6 h (depends on contact time with ulcer crater). Elimination:
90% in feces.
Assessment & Drug Effects
- Be aware of drug interactions and schedule other medications accordingly.
Patient & Family Education
- Although healing has occurred within the first 2 wk of therapy, treatment is usually continued 48 wk.
- Be aware that constipation is a drug-related problem. Follow these measures unless contraindicated: Increase water intake
to 810 glasses per day; increase physical exercise, increase dietary bulk. Consult physician: a suppository or bulk
laxative (e.g., Metamucil) may be prescribed.